To control the alarming spread of HIV, a vital need exists for developing an effective vaccine that would prevent individuals from becoming infected. In the context of NIAID-supported HIV vaccine research, identifying new vaccine concepts is the first step in the discovery and development of new vaccines. Basic research in HIV pathogenesis, immunology, virology, and development of animal models will form the basis for the identification of new vaccine concepts and will guide approaches for testing the most promising candidates in both domestic and international clinical trials (http://www3.niaid.nih.gov/research/topics/HIV/vaccines/).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Johnston, M. I. and Fauci, A. S. (2007) An HIV vaccine—evolving concepts, N. Engl. J. Med., 356(20), 2073–2081.
Letvin, N. L. (2005) Progress toward an HIV vaccine, Annu. Rev. Med., 56, 213–223.
Girard, M. P., Osmanov, S. K., and Kieny, M. P. (2006) A review of vaccine research and development: the human immunodeficiency virus (HIV), Vaccine, 24(19), 4062–4081.
Weiner, D. B. (2006) Progress in development and testing of novel recombinant vaccine platforms for HIV, Springer Seminars in Immunopathology, 28(3), 195–196.
Ensoli, B. (2005) Criteria for selection of HIV vaccine candidates—general principles, Microbes Infect., 7(14), 1433–1435.
Taub, D. D., Turcovski–Corrales, S. M., Key, M. L., Longo, D. L., and Murphy, W. J., (1986) Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro, J. Immunol., 156(6), 2095–2103.
Walker, C. M., Moody, D. J., Stites, D. P., et al. (1986) CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication, Science, 234, 1563–1566.
Janeway, C. A., Jr., Travers, P., Hunt, S., and Walport, M. (1997) Immunobiology: The Immune System in Health and Disease, 3rd ed., Garland, New York.
Spearman, P. (2006) Current progress in the development of HIV vaccines, Curr. Pharm. Des., 12, 1147–1167.
McMichael, A. J. (2006) HIV vaccines, Annu. Rev. Immunol., 24, 227–255.
Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., and Lusso, P. (1995) Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells, Science, 270, 1811–1815.
Zhao, A. and Kent, S. (1996) HIV-specific cytotoxic lymphocyte (CTL) responses control initial viremia in HIV infected macaques, 8th Annu. Conf. Australas. Soc. HIV Med., Sydney, Australia, November 14–17; 8:119 (Poster 139).
Pantaleo, G. and Koup, R. A. (2004) Correlates of immune protection in HIV-1 infection: what we know, what we don’t know, what we should know, Nat. Med., 10, 806–810.
Ogg, G. S., Jin, X., Bonhoeffer, S., et al. (1998) Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA, Science, 279, 2103–2106.
Koup, R. A., Safrit, J. T., Cao, Y., et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome, J. Virol., 68, 4650–4655.
Schmitz, J. E., Kuroda, M. J., Santra, S., et al. (1999) Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes, Science, 283, 857–860.
Richman, D. D., Wrin, T., Little, S. J., et al. (2003) Rapid evolution of the neutralizing antibody response to HIV type-1 infection, Proc. Natl. Acad. Sci. U.S.A., 100, 4144–4149.
Wei, X., Decker, J. M., Wang, S., et al. (2003) Antibody neutralization and escape by HIV-1, Nature, 422, 307–312.
Allen, T. M., O’Connor, D. H., and Jing P. (2000) Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viremia, Nature, 407, 386–390.
Goulder, P. J., Phillips, R. E., and Colbert, R. A. (1997) Late escape from an immunodominant cytotoxic T lymphocyte response associated with progression to AIDS, Nat. Med., 3, 212–217.
Letvin, N. L., Mascola, J. R., Sun, Y., et al. (2006) Preserved CD4(+) central memory T cells and survival in vaccinated SIV-challenged monkeys, Science, 312, 1530–1533.
Polacino, P. S., Stallard, V., Klaniecki, J. E., et al. (1999) Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in macaques, J. Virol., 73, 8201–8215.
Amara, R. R., Villinger, F., Altman, J. D., et al. (2001) Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine, Science, 292, 69–74.
Mattapallil, J. J., Douek, D. C., Buckler-White, A., et al. (2006) Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge, J. Exp. Med., 203, 1533–1541.
Gupta, S. B., Jacobson, L. P., Margolick, J. B., et al. (2207) Estimating the benefit of an HIV-1 vaccine that reduces viral load set point, J. Infect. Dis., 195, 546–550.
Barouch, D. H., Kunstman, J., Kuroda, M. J., et al. (2002) Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes, Nature, 415, 335–339.
Cohen, J. (2003) AIDS vaccine trial produces disappointment and confusion, Science, 299, 129–1291.
Yewdell, J. W. and Bennink, J. R. (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses, Annu. Rev. Immunol., 17, 51–88.
Ishioka, G. Y., Fikes, J., Hermanson, G., et al. (1999) Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes, J. Immunol., 162(7), 3915–3925.
McMichael, A. and Hanke, T. (2002) The quest for an AIDS vaccine: is the CD8+ T- cell approach feasible? Nat. Rev. Immunol., 2(4), 283–291.
Hanke, T., Samuel, R. V., Blanchard, T. J., et al. (1999) Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen, J. Virol., 73(9), 7524–7532.
Allen, T. M., Vogel, T. U., Fuller, D. H., et al. (2000) Induction of AIDS virus- specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen, J. Immunol., 164(9), 4968–4978.
Subbramanian, R. A., Kuroda, M. J., Charini, W. A., et al. (2003) Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys, J. Virol., 77(18), 10113–10118.
McEvers, K., Elrefaei, M., Norris, P., et al. (2005) Modified anthrax fusion proteins deliver HIV antigens through MHC class I and II pathways, Vaccine, 23(32), 4128–4135.
Mortara, L., Gras-Masse, H., Rommens, C., Venet, A., Guillet, J. G., and Bourgault- Villada, I. (1999) Type 1 CD4(+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques, J. Virol., 73(5), 4447–4451.
Gahery-Segard, H., Pialoux, G., Charmeteau, B., et al. (2000) Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine, J. Virol., 74(4), 1694–1703.
Pialoux, G., Gahery-Segard, H., Sermet, S., et al. (2001) Lipopeptides induce cell- mediated anti-HIV immune responses in seronegative volunteers, AIDS, 15(10), 1239–1249.
Duerr, A., Wasserheit, J. N., and Corey, L. (2006) HIV vaccines: new frontiers in vaccine development, Clin. Infect. Dis., 43, 500–511.
Elbasha, E. H. and Gumel, A. B. (2006) Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits, Bull. Math. Biol., 68, 577–614.
Shiver, J. W. and Emini, E. A. (2004) Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors, Annu. Rev. Med., 55, 355–372.
Roberts, D. M., Nanda, A., Havenga, M. J., et al. (2006) Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity, Nature, 441, 239–243.
Daniel, M. D., Kirchhoff, F., Czajak, S. C., et al. (1992) Protective effects of a live attenuated SIV vaccine with a deletion of the nef gene, Science, 258, 1938–1941.
Baba, T. W., Jeong, Y. S., Penninck, D., et al. (1995) Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques, Science, 267, 1820–1825.
Learmont, J. C., Geczy, A. F., Mills, J., et al. (1999) Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1, N. Engl. J. Med., 340, 1715–1722.
Donnelly, J. J., Ulmer, J. B., Shiver, J. W., et al. (1997) DNA vaccines, Annu. Rev. Immunol., 15, 617–648.
Egan, M. A., Charini, W. A., Kuroda, M. J., et al. (2000) Simian immunodeficiency virus (SIV) gag-DNA-vaccinated rhesus monkeys develop secondary cytotoxic T lymphocyte responses and control viral replication after pathogenic SIV infection, J. Virol., 74, 7485–7495.
Shen, L., Chen, Z. W., Miller, M. D., et al. (1991) Recombinant virus-vaccine- induced SIV-specific CD8+ cytotoxic T lymphocytes, Science, 252, 440–443.
Yasutomi, Y., Koenig, S., Haun, S. S., et al. (1993) Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys, J. Immunol., 150, 3101–3107.
Redfield, R. R., Wright, D. C., James, W. D., et al. (1987) Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease, N. Engl. J. Med., 316, 673–676.
Hirsch, V. M., Fuerst, T. R., Sutter, G., et al. (1996) Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara, J. Virol.,., 70, 3741–3752.
Santra, S., Schmitz, J. E., Kuroda, M. J., et al. (2002) Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys, J. Immunol., 168, 1847–1853.
Evans, T. G., Keefer, M. C., Weinhold, K. J., et al. (1999) A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp 120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers, J. Infect. Dis., 280, 290–298.
Shiver, J. W. and Emini, E. A. (2004) Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors, Annu. Rev. Med., 55, 355–372.
Shiver, J. W., Fu, T. M., Chen, L., et al. (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity, Nature, 415, 331–335.
Barouch, D. H., Pau, M. G., Custers, J. H., et al. (2004) Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity, J. Immunol., 172, 6290–6297.
Letvin, N. L., Huang, Y., Chakrabarti, B. K., et al. (2004) Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys, J. Virol., 78, 7490–7497.
Reitter, J. N., Means, R. E., and Desrosiers, R. C. (1998) A role for carbohydrates in immune evasion in AIDS, Nat. Med., 4, 679–684.
Ye, Y., Si, Z. H., Moore, J. P., et al. (2000) Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in simian-human immunodeficiency virus passaged in vivo, J. Virol., 74, 955–962.
Chan, D. C., Fass, D., Berger, J. M., et al. (1997) Core structure of gp41 from the HIV envelope glycoprotein, Cell, 93, 681–684.
D’Souza, M. P., Livnat, D., Bradac, J. A., et al. (1997) Evaluation of monoclonal antibodies to human immunodeficiency virus type-1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials, J. Infect. Dis., 175, 1056–1062.
Darren, P. W. H. I. and Burton, D. R.. (2001) The antiviral activity of antibodies in vitro and in vivo, Adv. Immunol., 77, 195–262.
Haynes, B. F., Fleming, J., St. Clair, E. W., et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies, Science, 308, 1906–1908.
Haynes, B. F., Moody, M. A., Verkoczy, L., Kelsoe, G., and Alam, S. M. (2005) Antibody polyspecificity and neutralization of HIV-1: a hypothesis, Hum. Antibodies, 14, 59–67.
Alam, S. M., McAdams, M., Boren, D., et al. (2007) The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes, J. Immunol., 178, 4424–4435.
Parren, P. W., Marx, P. A., Hessell, A. J., et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro, J. Virol., 75, 8340–8347.
O’Leary, J. G., Goodarzi, M., Drayton, D. L., and von Andrian, U. H. (2006) T cell- and B cell-independent adaptive immunity mediated by natural killer cells, Nat. Immunol., 7, 507–516.
Kawai, T. and Akira, S. (2006) Innate immune recognition of viral infection, Nat. Immunol., 7, 131–137.
Sugaya, M., Loré, K., Koup, R. A., Douek, D. C., and Blauvelt, A. (2004) HIV- infected Langerhans cells preferentially transmit virus to proliferating autologous CD4+ memory T cells located within Langerhans cell-T cell clusters, J. Immunol., 172, 2219–2224.
Roberts, D. M., Nanda, A., Havenga, M. J. E., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E., Gorgone, D. A., Lifton, M. A., Lemckert, A. A. C., Holterman, L., Chen, B., Dilraj, A., Carville, A., Mansfield, K. G., Goudsmit, J., and Barouch, D. H. (2006) Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity, Nature, 441, 239–243.
Liao, H.-X., Sutherland, L. L., Xia, S.-M., Brock, M. E., Scearce, R. M., Vanleeuwen, S., Alam, S. M., McAdams, M., Weaver, E. A., Camacho, Z. T., Ma, B.-J., Li, Y., Decker, J. M., Nabel, G. J., Montefiori, D. C., Hahn, B. H., Korber, B. T., Gao, F., and Haynes, B. F. (2006) A group M consensus envelope lycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses, Virology, 353(2) 268–282.
Zuñiga, R., Lucchetti, Z. R., Galvan, P., Sanchez, S., Sanchez, C., Hernandez, A., Sanchez, H., Frahm, N., Linde, C. H., Hewitt, H. S., Hildebrand, W., Altfeld, M., Allen, T. M., Walker, B. D., Korber, B. T., Leitner, T., Sanchez, J., and Brander, C. (2006) Relative dominance of gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control, J. Virol. 80(6), 3122–3125.
Moore, P. L., Crooks, E. T., Porter, L., Zhu, P., Cayanan, C. S., Grise, H., Corcoran, P., Zwick, M. B., Franti, M., Morris, L., Roux, K. H., Burton, D. R., and Binley, J. M. (2006) Nature of nonfunctional envelope proteins on the surface of the human immunodeficiency virus, J. Virol., 80(5), 2515–2528.
Song, R. J., Chenine, A.-L., Rasmussen, R. A., Ruprecht, C. R., Mirshahidi, S., Grisson, R. D., Xu, W., Whitney, J. B., Goins, L. M., Ong, H., Li, P.-L., Shai-Kobiler, E., Wang, T., McCann, C. M., Zhang, H., Wood, C., Kankasa, C., Secor, W. E., McClure, H. M., Strobert, E., Else, J. G., and Ruprecht, R. M. (2006) Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C env, J. Virol., 80(17), 8729–8738.
Van Rompay, K. K. A., Greenier, J. L., Cole, K. S., Earl, P., Moss, B., Steckbeck, J. D., Pahar, B., Rourke, T., Montelaro, R. C., Canfield, D. R., Tarara, R. P., Miller, C., McChesney, M. B., and Marthas, M. L. (2003) Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251, J. Virol., 77, 179–190.
Greenier, J. L., Van Rompay, K. K. A., Montefiori, D., Earl, P., Moss, B., and Marthas, M. L. (2005) Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals, Virol. J., 2, 11.
Lichterfeld, M., Kauffman, D. E., Yu, X. G., Mui, S. K., Addo, M. M., Johnston, M. N., Cohen, D., Robbins, G. K., Pae, E., Alter, G., Wurcel, A., Stone, D., Rosenberg, E. S., Walker, B. D., and Altfeld, M. (2004) Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV- specific CD4+ T cells, J. Exp. Med., 200(6), 701–712.
Goepfert, P. A., Horton, H., McElrath, M. J., Gurunathan, S., Ferrari, G., Tomaras, G. D., Montefiori, D. C., Allen, M., Chiu, Y-L., Spearman, P., Fuchs, J. D., Koblin, B. A., Blattner, W. A., Frey, S., Keefer, M. C., Baden, L. R., Corey, L., and the NIAID HIV Vaccine Trials Network (2005) High-dose recombinant canarypox vaccine expressing HIV-1 protein in seronegative human subjects, J. Infect. Dis., 192(7), 1249–1259.
Price, D. A., West, S. M., Betts, M. R., Ruff, L. E., Brenchley, J. M., Ambrozak, D. R., Edghill-Smith, Y., Kuroda, M. J., Bogdan, D., Kunstman, K., Letvin, N. L., Franchini, G., Wolinsky, S. M., Koup, R. A., and Douek, D. C. (2004) T cell receptor recognition motifs govern immune escape patterns in acute SIV infection, Immunity, 21, 793–803.
Bihl, F., Frahm, N., Di Giammarino, L., Sidney, J., John, M., Yusin, K., Woodberry, T., Sango, K., Hewitt, H. S., Henry, L., Linde, C. H., Chisholm III, J. V., Zaman, T. M., Pae, E., Mallal, S., Walker, B. D., Sette, A., Korber, B. T., Heckerman, D., and Brander, C. (2006) The impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses, J. Immunol., 176(7), 4094–4101.
Frahm, N., Kiepiela, P., Adams, S., Linde, C. H., Hewitt, H. S., Sango, K., Feeney, M. E., Addo, M. M., Lichterfeld, M., Lahaie, M. P., Pae, E., Wurcel, A. G., Roach, T., St. John, M. A., Altfeld, M., Marincola, F. M., Moore, C., Mallal, S., Carrington, M., Heckerman, D., Allen, T. M., Mullins, J. I., Korber, B. T., Goulder, P. J. R., Walker, B. D., and Brander, C. (2006) Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes, Nat. Immunol., 7, 173–178.
Khurana, S., Needham, J., Mathieson, B., Rodriguez-Chavez, I. R., Catanzaro, A. T., Bailer, R. T., Kim, J., Polonis, V., Cooper, D. A., Guerin, J., Peterson, M. L., Gurwith, M., Nguyen, N., Graham, B. S., Golding, H., and the HIV Vaccine Trial Network (2006) Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies. J. Virol., 80(5), 2092–2099.
Khurana, S., Needham, J., Park, S., et al. (2006) Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes, J. Acquir. Immune Defic. Syndr., 43(3), 304–312.
Pantaleo, G. (2008) HIV-1 T-cell vaccines: evaluating the next step, Lancet Infect. Dis., 8(2), 82–83.
Cohen, J. (2007) AIDS research. Did Merck’s failed HIV vaccine cause harm? Science, 318, 1048–1049.
Ledford, H. (2007) HIV vaccine may raise risk, Nature, 450, 325.
Desrosiers, R. (2008) Scientific obstacles to an effective HIV vaccine, 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3–6, abstract 92.
Sekaly, R.-P. (2007) The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med., 205(1), 7–12.
Shiver, J. W., Fu, T. M., Chen, L., Casimiro, D. R., Davies, M. E., Evans, R. K., Zhang, Z. Q., Simon, A. J., Trigona, W. L., Dubey, S. A., et al. (2002) Replication- incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity, Nature, 415, 331–335.
Casimiro, D. R., Wang, F., Schleif, W.A., Liang, X., Zhang, Z. Q., Tobery, T. W., et al. (2005) Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag, J. Virol., 79, 15547–15555.
Gomez-Roman, V. R., Florese, R. H., Peng, B., Montefiori, D. C., Kalyanaraman, V. S., Venzon, D. et al. (2006) An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains, J. Acquir. Immune Defic. Syndr., 4, 270–277.
Barouch, D. H., and Nabel. G. J. (2005) Adenovirus vector-based vaccines for human immunodeficiency virus type 1, Hum. Gene Ther., 16, 149–156.
Kostense, S., Koudstaal, W., Sprangers, M., Weverling, G. J., Penders, G., et al. (2004) Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector, AIDS, 18, 1213–1216.
Sumida, S. M., Truitt, D. M., Lemckert, A. A., Vogels, R., Custers, J. H., et al. (2005) Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein, J. Immunol., 174, 7179–7185.
Roberts, D. M., Nanda, A., Havenga, M. J., Abbink, P., Lynch, D. M., Ewald, B. A., et al. (2006) Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity, Nature, 441, 239–243.
Cohen, J. (2007) Did Merck’s failed HIV vaccine cause harm? Science, 318(5853), 1048–1049.
NIAID Statement (2007) Immunizations are discontiued in two HIV vaccine trials (http://www3.niaid.nih.gov/news/newsreleases/2007/step_statement.htm).
Borkow, G. (2005) Mouse models for HIV-1 infection, IUBMB Lif, 57, 819–823.
Hu, S.L. (2005) Non-human primate models for AIDS vaccine research, Curr. Drug Targets Infect. Disord., 5, 193–201.
ScienceScope. (2007) New scrutiny on vaccine trial, Science, 318(5851), 529.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Georgiev, V.S. (2009). Vaccine Development. In: Georgiev, V.S. (eds) National Institute of Allergy and Infectious Diseases, NIH. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-60327-297-1_35
Download citation
DOI: https://doi.org/10.1007/978-1-60327-297-1_35
Publisher Name: Humana Press
Print ISBN: 978-1-60327-296-4
Online ISBN: 978-1-60327-297-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)